BioSpace News Archive

Neuroinflammation collaboration targeting inflammasome steps-up-the-pace in race for Alzheimer’s disease medicines that alleviate the burden of devastating disease

Solid full year 2020 results in a COVID-19 environment, with Group sales growth of 3.0%1 and Core Operating margin at 32.0%

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced that the Company will release fourth quarter and fiscal year 2020 operating results after the close of the market on Monday, March 1, 2021.

Lucira Health, Inc., announced that U.S. physicians and healthcare providers can now order Lucira COVID-19 All-In-One Test Kits online from lucirahealth.com.

-- Revenues of $1.04 Billion in 2020, GAAP Loss per Share of $0.70 and Basic and Diluted Non-GAAP Earnings per Share of $0.43 -- -- Financial Expectations for 2021 Reflect Anticipated Growth of Proprietary Products and Investment in Strategic Priorities for Long-Term Value Creation --

ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer, today provided a corporate update and reported financial results for the fiscal first quarter ended December 31, 2020 .

Ensoma, a company that formally launched today with the mission of expanding the curative power of genomic medicine by pioneering a next-generation in vivo approach, announced it has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”)

Desai to play a key role in helping guide the clinical research program for the company’s novel lead candidate RP-0320 and additional programs stemming from its MMA drug development platform

Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium - Combination of eganelisib with nivolumab demonstrated improved ORR, DCR, and PFS versus 2L standard of care nivolumab monotherapy -

Revenue: Q4 of $4.5 billion, up from $3.0 billion last year; Full year of $14.0 billion, up from $11.6 billion last year Diluted EPS: Q4 of $9.54, up from $2.32 last year; Full year of $15.88, up from $8.35 last year Adjusted EPS: Q4 of $10.56, up from $2.86 last year; Full year of $23.94, up from $11.32 last year